Equillium: Multi-Cytokine Platform To Go Beyond Scope Of EQ504 For UC

2026-02-25 17:24:17 ET

The last time I spoke about Equillium ( EQ ) it was with respect to a Seeking Alpha article entitled " Equillium: Pushing Forward With AhR Activation Drug Candidate EQ504 For UC ". With respect to this article, I went over the fact that the company was in the process of advancing its potent, selective oral AhR modulator EQ504 for the treatment of patients with Ulcerative Colitis [UC]. The company still intends to initiate a phase 1 single-ascending dose/multiple-ascending dose [SAD/MAD] study using EQ504 to treat these UC patients in mid-2026. Upon trial initiation, the company believes that it is going to be able to release initial data from this SAD/MAD early-stage trial six months later....

Read the full article on Seeking Alpha

For further details see: